Literature DB >> 30093631

Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.

Linping Chen-Wichmann1, Marina Shvartsman1, Caro Preiss1, Colin Hockings2, Roland Windisch1, Enric Redondo Monte3, Georg Leubolt3, Karsten Spiekermann3,4,5, Jörn Lausen6, Christian Brendel7, Manuel Grez8, Philipp A Greif3,4,5, Christian Wichmann9.   

Abstract

Chromosomal translocations represent frequent events in leukemia. In t(8;21)+ acute myeloid leukemia, RUNX1 is fused to nearly the entire ETO protein, which contains four conserved nervy homology regions, NHR1-4. Furthermore RUNX1/ETO interacts with ETO-homologous proteins via NHR2, thereby multiplying NHR domain contacts. As shown recently, RUNX1/ETO retains oncogenic activity upon either deletion of the NHR3 + 4 N-CoR/SMRT interaction domain or substitution of the NHR2 tetramer domain. Thus, we aimed to clarify the specificities of the NHR domains. A C-terminally NHR3 + 4 truncated RUNX1/ETO containing a heterologous, structurally highly related non-NHR2 tetramer interface translocated into the nucleus and bound to RUNX1 consensus motifs. However, it failed to interact with ETO-homologues, repress RUNX1 targets, and transform progenitors. Surprisingly, transforming capacity was fully restored by C-terminal fusion with ETO's NHR4 zinc-finger or the repressor domain 3 of N-CoR, while other repression domains failed. With an inducible protein assembly system, we further demonstrated that NHR4 domain activity is critically required early in the establishment of progenitor cultures expressing the NHR2 exchanged truncated RUNX1/ETO. Together, we can show that NHR2 and NHR4 domains can be replaced by heterologous protein domains conferring tetramerization and repressor functions, thus showing that the NHR2 and NHR4 domain structures do not have irreplaceable functions concerning RUNX1/ETO activity for the establishment of human CD34+ cell expansion. We could resemble the function of RUNX1/ETO through modular recomposition with protein domains from RUNX1, ETO, BCR and N-CoR without any NHR2 and NHR4 sequences. As most transcriptional repressor proteins do not comprise tetramerization domains, our results provide a possible explanation as to the reason that RUNX1 is recurrently found translocated to ETO family members, which all contain tetramer together with transcriptional repressor moieties.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30093631     DOI: 10.1038/s41388-018-0441-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia.

Authors:  M C Guastadisegni; A Lonoce; L Impera; F Di Terlizzi; G Fugazza; S Aliano; R Grasso; T Cluzeau; S Raynaud; M Rocchi; C T Storlazzi
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

2.  Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.

Authors:  Sangho Park; Wei Chen; Tomasz Cierpicki; Marco Tonelli; Xiongwei Cai; Nancy A Speck; John H Bushweller
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

3.  The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.

Authors:  James C Mulloy; Jörg Cammenga; Karen L MacKenzie; Francisco J Berguido; Malcolm A S Moore; Stephen D Nimer
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.

Authors:  Ming Yan; Eiki Kanbe; Luke F Peterson; Anita Boyapati; Yuqin Miao; Yang Wang; I-Ming Chen; Zixing Chen; Janet D Rowley; Cheryl L Willman; Dong-Er Zhang
Journal:  Nat Med       Date:  2006-07-30       Impact factor: 53.440

5.  Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.

Authors:  Kevin A Link; Shan Lin; Mahesh Shrestha; Melissa Bowman; Mark Wunderlich; Clara D Bloomfield; Gang Huang; James C Mulloy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

6.  The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO.

Authors:  Jörn Lausen; Seongeun Cho; Shaohua Liu; Milton H Werner
Journal:  J Biol Chem       Date:  2004-09-17       Impact factor: 5.157

7.  Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes.

Authors:  Colin Kwok; Bernd B Zeisig; Jihui Qiu; Shuo Dong; Chi Wai Eric So
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

8.  t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.

Authors:  Akiko J Okumura; Luke F Peterson; Fumihiko Okumura; Anita Boyapati; Dong-Er Zhang
Journal:  Blood       Date:  2008-05-29       Impact factor: 22.113

9.  Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells.

Authors:  Akiko Joo Okumura; Luke F Peterson; Miao-Chia Lo; Dong-Er Zhang
Journal:  Exp Hematol       Date:  2007-06       Impact factor: 3.084

10.  MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.

Authors:  Nicole Kohrs; Stephan Kolodziej; Olga N Kuvardina; Julia Herglotz; Jasmin Yillah; Stefanie Herkt; Alexander Piechatzek; Gabriela Salinas Riester; Thomas Lingner; Christian Wichmann; Halvard Bonig; Erhard Seifried; Uwe Platzbecker; Hind Medyouf; Manuel Grez; Jörn Lausen
Journal:  PLoS Genet       Date:  2016-03-18       Impact factor: 5.917

View more
  3 in total

1.  Defined Human Leukemic CD34+ Liquid Cultures to Study HDAC/Transcriptional Repressor Complexes.

Authors:  Roland Windisch; Sophie Kreissig; Christian Wichmann
Journal:  Methods Mol Biol       Date:  2023

2.  Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.

Authors:  Hélène Jakobczyk; Lydie Debaize; Benoit Soubise; Stéphane Avner; Jérémie Rouger-Gaudichon; Séverine Commet; Yan Jiang; Aurélien A Sérandour; Anne-Gaëlle Rio; Jason S Carroll; Christian Wichmann; Michael Lie-A-Ling; Georges Lacaud; Laurent Corcos; Gilles Salbert; Marie-Dominique Galibert; Virginie Gandemer; Marie-Bérengère Troadec
Journal:  J Hematol Oncol       Date:  2021-03-20       Impact factor: 17.388

3.  Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects.

Authors:  Mohanraj Gopalswamy; Tobias Kroeger; David Bickel; Benedikt Frieg; Shahina Akter; Stephan Schott-Verdugo; Aldino Viegas; Thomas Pauly; Manuela Mayer; Julia Przibilla; Jens Reiners; Luitgard Nagel-Steger; Sander H J Smits; Georg Groth; Manuel Etzkorn; Holger Gohlke
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.